Sanofi to set up factory in Singapore for vaccine production on “massive scale”

French pharma major Sanofi said it will invest €400 million set up a vaccine production site in Singapore to produce innovative vaccines “on a massive scale” for Asia and quickly respond to future pandemic risks.

The investment would be made over five years, and the facility would complement Sanofi’s existing manufacturing capacities in Europe and North America and become a “regional center of excellence” for vaccine production in Asia, the company said on April 12.

The vaccine production site, set up in partnership with the Singapore Economic Development Board,  would use the latest manufacturing practices and digital technologies, is expected to create up to 200 local jobs and enhance Singapore’s position as a regional innovation hub for the healthcare industry, it added.

“Ever-growing global demand” for vaccines

 “As a major healthcare player, it’s our responsibility to act and meet the unprecedented growing demands for vaccines. By investing in a new production site in Singapore, Sanofi is aiming to strengthen production capacity to meet ever-growing global demands for vaccines, and answer more rapidly to future pandemics,” Thomas Triomphe, executive vice president and global head of Sanofi Pasteur, the vaccine division of the Sanofi group, said.

The factory will be designed around a central unit with several fully digitalised modules that allow production of three to four vaccines simultaneously, as compared to only one in current industrial sites, the company noted.

The project is currently entering the design phase with construction expected to begin in the third quarter of 2021. It would become fully operational at the beginning of 2026 once all qualifications and validations of the first manufactured vaccine have been completed.



Support ASEAN news

Investvine has been a consistent voice in ASEAN news for more than a decade. From breaking news to exclusive interviews with key ASEAN leaders, we have brought you factual and engaging reports – the stories that matter, free of charge.

Like many news organisations, we are striving to survive in an age of reduced advertising and biased journalism. Our mission is to rise above today’s challenges and chart tomorrow’s world with clear, dependable reporting.

Support us now with a donation of your choosing. Your contribution will help us shine a light on important ASEAN stories, reach more people and lift the manifold voices of this dynamic, influential region.

$
Personal Info

Donation Total: $10.00

 

 

French pharma major Sanofi said it will invest €400 million set up a vaccine production site in Singapore to produce innovative vaccines “on a massive scale” for Asia and quickly respond to future pandemic risks. The investment would be made over five years, and the facility would complement Sanofi’s existing manufacturing capacities in Europe and North America and become a “regional center of excellence” for vaccine production in Asia, the company said on April 12. The vaccine production site, set up in partnership with the Singapore Economic Development Board,  would use the latest manufacturing practices and digital technologies, is expected...

French pharma major Sanofi said it will invest €400 million set up a vaccine production site in Singapore to produce innovative vaccines “on a massive scale” for Asia and quickly respond to future pandemic risks.

The investment would be made over five years, and the facility would complement Sanofi’s existing manufacturing capacities in Europe and North America and become a “regional center of excellence” for vaccine production in Asia, the company said on April 12.

The vaccine production site, set up in partnership with the Singapore Economic Development Board,  would use the latest manufacturing practices and digital technologies, is expected to create up to 200 local jobs and enhance Singapore’s position as a regional innovation hub for the healthcare industry, it added.

“Ever-growing global demand” for vaccines

 “As a major healthcare player, it’s our responsibility to act and meet the unprecedented growing demands for vaccines. By investing in a new production site in Singapore, Sanofi is aiming to strengthen production capacity to meet ever-growing global demands for vaccines, and answer more rapidly to future pandemics,” Thomas Triomphe, executive vice president and global head of Sanofi Pasteur, the vaccine division of the Sanofi group, said.

The factory will be designed around a central unit with several fully digitalised modules that allow production of three to four vaccines simultaneously, as compared to only one in current industrial sites, the company noted.

The project is currently entering the design phase with construction expected to begin in the third quarter of 2021. It would become fully operational at the beginning of 2026 once all qualifications and validations of the first manufactured vaccine have been completed.



Support ASEAN news

Investvine has been a consistent voice in ASEAN news for more than a decade. From breaking news to exclusive interviews with key ASEAN leaders, we have brought you factual and engaging reports – the stories that matter, free of charge.

Like many news organisations, we are striving to survive in an age of reduced advertising and biased journalism. Our mission is to rise above today’s challenges and chart tomorrow’s world with clear, dependable reporting.

Support us now with a donation of your choosing. Your contribution will help us shine a light on important ASEAN stories, reach more people and lift the manifold voices of this dynamic, influential region.

$
Personal Info

Donation Total: $10.00

 

 

NO COMMENTS

Leave a Reply